Recombinant Human ApoC2 (C-6His)

Catalog No: CB66

Description	Recombinant Human Apolipoprotein C-II is produced by our E.coli expression system and the target gene encoding Thr23-Glu101 is expressed with a 6His tag at the C-terminus.
Source	E. coli
Alternative name	Apolipoprotein C-II; Apolipoprotein C2; APC2 and APOC2
Accession No.	AAP35354.1
Predicted Molecular Weight	10kDa
AP Molecular Weight	14kDa, reducing conditions.
Formulation	Supplied as a 0.2 μm filtered solution of PBS, 50% Glycerol, pH 7.4.
Reconstitution	Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Quality Control	Purity: Greater than 95% as determined by reducing SDS-PAGE. Endotoxin: Less than 0.1 ng/μg (1 IEU/μg) as determined by LAL test.
Shipping	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Storage	Store at < -20°C, stable for 6 months after receipt. Please minimize freeze-thaw cycles.
Background	APOC2 activates the lipoprotein lipase in capillaries, which hydrolyzes triglycerides and thus provides free fatty acids for cells. APOC2 is component of the very low density lipoprotein (VLDL) fraction in plasma. It is also an activator of several triacylglycerol lipases. The association of APOC2 with plasma chylomicrons, VLDL, and HDL is reversible, a function of the secretion and catabolism of triglyceride-rich lipoproteins, and changes rapidly. Defects in APOC2 are the cause of hyperlipoproteinemia type 1B (HLPP1B) which characterized by hypertriglyceridemia, xanthomas, and increased risk of pancreatitis and early atherosclerosis.
SDS-Page